首页> 美国卫生研究院文献>Cancer Medicine >Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

【2h】

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

机译：在不同组织学类型的晚期非小细胞肺癌患者中阿洛替尼作为三线或三线疗法的疗效：ALTER0303试验中的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Anlotinib showed significant survival benefits in advanced non‐small cell lung cancer (NSCLC) patients as a third‐ or further‐line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies.

机译：在ALTER0303试验中，作为第三线或进一步治疗方案，安洛替尼在晚期非小细胞肺癌（NSCLC）患者中显示出显着的生存获益。我们旨在评估阿洛替尼在不同组织学患者中的疗效。

著录项

期刊名称 Cancer Medicine
作者
Ying Cheng; Baohui Han; Kai Li; Qiming Wang; Li Zhang; Jianhua Shi; Zhehai Wang; Jianxing He; Yuankai Shi; Weiqiang Chen; Xiuwen Wang; Yi Luo; Kejun Nan; Faguang Jin; Baolan Li; Jing Zhu;
展开▼
作者单位

展开▼
年(卷),期 2020(9),8
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
ACC; anlotinib; antiangiogenesis; SCC; third‐line;

机译：ACC;阿洛替尼;抗血管生成;SCC;三线;
入库时间 2022-08-21 11:36:49

相似文献

外文文献
中文文献
专利

1. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial [J] . Ying Cheng, Baohui Han, Kai Li, Cancer Medicine . 2020,第8期

机译：Anlotinib作为具有不同组织学类型的晚期非小细胞肺癌患者的第三或进一步疗法的影响：ALTER0303试验中的亚组分析
2. Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial [J] . Jianhua Shi, Guimin Chen, Haitao Wang, Thoracic cancer. . 2021,第17期

机译：在鳞状细胞肺癌患者（SCC）患者中，第三线ANLOTINIB期间的发生高血压发生与患者的无进展生存期有关：ALRET0303试验的后HOC分析
3. The Impact of Anlotinib on Brain Metastases of Non‐Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303) [J] . Jiang Shunjun, Liang Hengrui, Liu Zhichao, The oncologist . 2020,第5期

机译：Anlotinib对非小细胞肺癌脑转移的影响：HOC分析III期随机对照试验（ALTER0303）
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial [O] . Lili Wang, Zhen He, Sen Yang, 2019

机译：先前治疗策略对盐酸安洛替尼作为三线治疗对晚期非小细胞肺癌（NSCLC）患者的疗效的影响：ALTER0303试验的亚组分析
7. Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial [O] . Ying Cheng, Baohui Han, Kai Li, 2020

机译：Anlotinib作为具有不同组织学类型的晚期非小细胞肺癌患者的第三或进一步疗法的影响：ALTER0303试验中的亚组分析

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

摘要

著录项

相似文献

相关主题

期刊订阅